ENDOSTEM
Activation of vasculature associated stem cells and muscle stem cells for the repair and maintenance of muscle tissue
| Coordinatore | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6
Organization address
address: Place Jussieu 4 contact info |
| Nazionalità Coordinatore | France [FR] |
| Totale costo | 16˙340˙569 € |
| EC contributo | 11˙997˙580 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-single-stage |
| Funding Scheme | CP-IP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-01-01 - 2014-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6
Organization address
address: Place Jussieu 4 contact info |
FR (PARIS) | coordinator | 1˙871˙947.50 |
| 2 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 1˙850˙008.40 |
| 3 |
UNIVERSIDAD POMPEU FABRA
Organization address
address: PLACA DE LA MERCE 10-12 contact info |
ES (BARCELONA) | participant | 751˙300.00 |
| 4 |
IRCCS - ASSOCIAZIONE LA NOSTRA FAMIGLIA 'ISTITUTO SCIENTIFICO EUGENIO MEDEA'
Organization address
address: VIA DON LUIGI MONZA 1 contact info |
IT (PONTE LAMBRO) | participant | 750˙200.00 |
| 5 |
SANTHERA PHARMACEUTICALS (SCHWEIZ) AG
Organization address
address: HAMMERSTRASSE 49 contact info |
CH (LIESTAL) | participant | 748˙800.00 |
| 6 |
ITALFARMACO SPA
Organization address
address: VIALE FULVIO TESTI 330 contact info |
IT (MILANO) | participant | 683˙400.00 |
| 7 |
CONSIGLIO NAZIONALE DELLE RICERCHE
Organization address
address: Piazzale Aldo Moro 7 contact info |
IT (ROMA) | participant | 639˙300.00 |
| 8 |
HMGBiotech s.r.l.
Organization address
address: via Moretto da Brescia 25 contact info |
IT (Milano) | participant | 552˙500.00 |
| 9 |
EUROPEAN MOLECULAR BIOLOGY LABORATORY
Organization address
address: Meyerhofstrasse 1 contact info |
DE (HEIDELBERG) | participant | 513˙300.00 |
| 10 |
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Organization address
address: BATIMENT CE 3316 STATION 1 contact info |
CH (LAUSANNE) | participant | 490˙500.00 |
| 11 |
JOHANN WOLFGANG GOETHE UNIVERSITAET FRANKFURT AM MAIN
Organization address
address: GRUNEBURGPLATZ 1 contact info |
DE (FRANKFURT AM MAIN) | participant | 489˙300.00 |
| 12 |
Fondazione Centro San Raffaele
Organization address
address: Via Olgettina 60 contact info |
IT (Milano) | participant | 483˙700.00 |
| 13 |
IFOM FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE
Organization address
address: "Via Adamello, 16" contact info |
IT (MILAN) | participant | 463˙700.00 |
| 14 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | participant | 452˙289.03 |
| 15 |
DANDO WEISS & COLUCCI LIMITED
Organization address
address: LOWER BRISTOL ROAD MINERVA HOUSE contact info |
UK (BATH) | participant | 299˙524.16 |
| 16 |
FONDAZIONE TELETHON
Organization address
address: VIA VARESE 16/B contact info |
IT (ROMA) | participant | 278˙077.20 |
| 17 |
NOVARTIS PHARMA AG
Organization address
address: LICHTSTRASSE 35 contact info |
CH (BASEL) | participant | 259˙100.00 |
| 18 |
LIVERPOOL JOHN MOORES UNIVERSITY
Organization address
address: Egerton Court Rodney Street 2 contact info |
UK (LIVERPOOL) | participant | 256˙248.00 |
| 19 |
FONDAZIONE SANTA LUCIA
Organization address
address: VIA ARDEATINA 306 contact info |
IT (Roma) | participant | 164˙385.75 |
| 20 |
ACCELERON MEDICINES LTD
Organization address
address: NEW STREET SQUARE 5 contact info |
UK (London) | participant | 0.00 |
| 21 |
CORETHERAPIX S.L
Organization address
address: PLAZA DE LA ENCINA 10 NUCLEO 1 PLANTA 3 contact info |
ES (MADRID) | participant | 0.00 |
| 22 |
FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR
Organization address
address: Via Olgettina 60 contact info |
IT (MILANO) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'We propose to develop new strategies to mobilize skeletal muscle tissue-associated stem cells as a tool for efficient tissue repair. This will be combined with exploring novel approaches that limit tissue damage, and will focus on agents that modify muscle and muscle vasculature progenitor cells. These molecules include nitric oxide associated with non-steroidal anti-inflammatory drugs, HMGB1, Cripto, NAC, and present and improved deacetylase inhibitors. Three clinical trials will be run in tandem with efforts to dissect the underlying mechanisms of action. Importantly, we have already initiated a monocentric clinical trial that focuses on the efficacy of NO-donors plus NSAIDs in muscle pathologies. Our efforts will be complemented by novel biodelivery systems for effective targeting. Our efforts will be complemented by novel biodelivery systems for effective targeting. The most promising drugs, used alone or in combination, will be first validated in small and large animal models. Our project brings together leading investigators to examine how vascular and muscle progenitors participate in postnatal growth and muscle tissue repair. A key issue that this project addresses is the tissue environment in which endogenous stem cells are activated. We propose that muscle degeneration and fibrosis provokes altered vascularization and immune responses, which eventually affect negatively stem cell functions. Molecules that can be used to therapeutically target these key cells, and their communication with neighboring vascular, inflammatory and fibrotic cell types, will lead to more effective approaches to muscle regenerative medicine and to novel cures for degenerative diseases, including atherosclerosis, vascular damage in diabetes and in peripheral ischemic vascular disease.'
Altri progetti dello stesso programma (FP7-HEALTH)
MERCURIC (2013)
A Phase Ib/II study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor PF-02341066 in KRASMT and KRASWT (with aberrant c-MET) Colorectal Cancer Patients
Read MoreTUMADOR (2013)
Development of very promising humanized therapeutic mAbs efficiently neutralizing a novel immunosuppressive pathway involved in a wide range of cancers
Read More